We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
DXS International Plc | AQSE:DXSP | Aquis Stock Exchange | Ordinary Share | GB00B2Q6HZ92 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.35 | 1.00 | 2.20 | 1.60 | 1.35 | 1.35 | 0.00 | 15:29:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMDXSP
DXS INTERNATIONAL PLC
Holding in Company and Total Voting Rights
The Board of DXS International plc (the "Company"), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification under the DTR that following the Placing announced on 17 May 2023, the following persons have voting rights in the Company as follows:
3. Details of person subject to the notification obligation (iv) Name Foresight Group LLP City and country of registered office (if applicable) London, UK 4. Full name of shareholder(s) (if different from 3.) (v) --------------------------------------------------------------------------------------------- Name Thames Ventures VCT 1 plc ----------------------------------- -------------------------------------------------------- City and country of registered office (if applicable) London, UK ----------------------------------- -------------------------------------------------------- 5. Date on which the threshold was crossed or reached (vi) : 24.05.23 ----------------------------------- -------------------------------------------------------- 6. Date on which issuer notified (DD/MM/YYYY): 24.05.23 ----------------------------------- -------------------------------------------------------- 7. Total positions of person(s) subject to the notification obligation --------------------------------------------------------------------------------------------- Total number % of voting rights of voting rights % of voting rights through financial held in issuer attached to shares instruments (total Total of both (8.A + 8.B) (total of 8. A) of 8.B 1 + 8.B 2) in % (8.A + 8.B) (vii) -------------- ------------------- ------------------ ----------------- ----------------- Resulting situation on the date on which threshold was crossed or reached 11.71 11.71 7,500,000 -------------- ------------------- ------------------ ----------------- ----------------- Position n/a n/a n/a of previous notification (if applicable) -------------- ------------------- ------------------ ----------------- ----------------- 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached (viii) ---------------------------------------------------------------------------- A: Voting rights attached to shares ---------------------------------------------------------------------------- Class/type of shares ISIN code (if possible) Number of voting rights (ix) % of voting rights ------------------ Direct Indirect Direct Indirect (DTR5.1) (DTR5.2.1) (DTR5.1) (DTR5.2.1) ------------------ -------------- -------------- ---------- ------------ GB00B2Q6HZ92 7,500,000 n/a 11.71 n/a ------------------ -------------- -------------- ---------- ------------ SUBTOTAL 8. A 7,500,000 11.71 ------------------ ------------------------------ ------------------------
In accordance with the FCA's Disclosure Guidance and Transparency Rules, as at 24 May 2023 the Company's issued share capital consists of 64,022,124 Ordinary Shares of 0.33pence each, each with one voting right. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 64,022,124.
The above figure of 64,022,124 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Directors of DXS International plc accept responsibility for this announcement
Enquiries:
David Immelman (Chief Executive) 01252 719800 DXS International plc david@dxs-systems.com Wrecclesham House Wrecclesham Road Farnham Surrey GU10 4PS www.dxs-systems.co.uk Corporate Advisor David Papworth City & Merchant 0207 101 7676 Corporate Broker Hybridan LLP Claire Louise Noyce 020 3764 2341
Note to Editors:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.
(END) Dow Jones Newswires
May 25, 2023 02:00 ET (06:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year DXS Chart |
1 Month DXS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions